|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/13/14 Anavex Life Sciences Corp. 10-Q 6/30/14 55:4.6M Newsfile Corp/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report -- form10q HTML 270K
2: EX-31.1 Certification -- §302 - SOA'02 -- exhibit31-1 HTML 20K
3: EX-32.1 Certification -- §906 - SOA'02 -- exhibit32-1 HTML 18K
34: R1 Document and Entity Information HTML 44K
25: R2 Interim Condensed Consolidated Balance Sheets HTML 78K
32: R3 Interim Condensed Consolidated Balance Sheets HTML 27K
(Parenthetical)
36: R4 Interim Condensed Consolidated Statements of HTML 70K
Operations
49: R5 Interim Condensed Consolidated Statements of Cash HTML 89K
Flows
26: R6 Consolidated Statement of Changes in Capital HTML 58K
Deficit
31: R7 Business Description, Basis of Presentation and HTML 31K
Liquidity
22: R8 Recent Accounting Pronouncements HTML 25K
16: R9 Equipment HTML 25K
50: R10 Derivative Liabilities HTML 25K
38: R11 Promissory Notes Payable HTML 31K
37: R12 Senior Convertible Debentures HTML 34K
42: R13 Capital Stock HTML 27K
43: R14 Lincoln Park Purchase Agreement HTML 24K
41: R15 Related Party Transactions HTML 28K
44: R16 Commitments HTML 69K
33: R17 Supplemental Cash Flow Information HTML 21K
35: R18 Equipment (Tables) HTML 24K
40: R19 Derivative Liabilities (Tables) HTML 21K
55: R20 Promissory Notes Payable (Tables) HTML 23K
46: R21 Senior Convertible Debentures (Tables) HTML 30K
28: R22 Commitments (Tables) HTML 65K
39: R23 Business Description, Basis of Presentation and HTML 24K
Liquidity (Narrative) (Details)
30: R24 Derivative Liabilities (Narrative) (Details) HTML 17K
13: R25 Promissory Notes Payable (Narrative) (Details) HTML 38K
47: R26 Senior Convertible Debentures (Narrative) HTML 50K
(Details)
52: R27 Capital Stock (Narrative) (Details) HTML 37K
19: R28 Lincoln Park Purchase Agreement (Narrative) HTML 42K
(Details)
18: R29 Related Party Transactions (Narrative) (Details) HTML 49K
20: R30 Commitments (Narrative) (Details) HTML 84K
21: R31 Supplemental Cash Flow Information (Narrative) HTML 19K
(Details)
23: R32 Schedule of Property, Plant and Equipment HTML 28K
(Details)
12: R33 Derivative Liabilities Activity (Details) HTML 35K
45: R34 Schedule of Debt (Details) HTML 48K
27: R35 Schedule Of Convertible Debt (Details) HTML 27K
29: R36 Company Issuance of Share Purchase Warrants HTML 34K
(Details)
15: R37 Fair Value of the Purchaser and Non-Purchaser HTML 24K
Warrants at Issuance (Details)
54: R38 Schedule of Stockholders' Equity Note, Warrants or HTML 45K
Rights, Activity (Details)
10: R39 Schedule of Stockholders' Equity Note, Warrants or HTML 38K
Rights (Details)
24: R40 Schedule of Share-based Compensation, Stock HTML 61K
Options, Activity (Details)
48: R41 Schedule of Share-based Payment Award, Stock HTML 33K
Options, Valuation Assumptions (Details)
14: R42 Schedule of Nonvested Share Activity (Details) HTML 70K
53: XML IDEA XML File -- Filing Summary XML 81K
11: EXCEL IDEA Workbook of Financial Reports XLSX 81K
17: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 321K
4: EX-101.INS XBRL Instance -- avxl-20140630 XML 453K
6: EX-101.CAL XBRL Calculations -- avxl-20140630_cal XML 126K
7: EX-101.DEF XBRL Definitions -- avxl-20140630_def XML 1.21M
8: EX-101.LAB XBRL Labels -- avxl-20140630_lab XML 2.50M
9: EX-101.PRE XBRL Presentations -- avxl-20140630_pre XML 1.31M
5: EX-101.SCH XBRL Schema -- avxl-20140630 XSD 443K
51: ZIP XBRL Zipped Folder -- 0001062993-14-004769-xbrl Zip 165K
| Anavex Life Sciences Corp. - Exhibit 31.1 - Filed by newsfilecorp.com |
Exhibit 31.1
CERTIFICATION
I, Christopher Missling, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q for the three months ended June 30, 2014 of Anavex Life Sciences Corp. (the “registrant”);
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:
(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: August 12, 2014
/s/Christopher Missling, PhD
__________________________________________
Christopher Missling, PhD
Chief Executive Officer and Chief Financial Officer
(Principal Executive, Financial and Accounting Officer)
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed as of: | 8/13/14 | None on these Dates | ||
| Filed on: | 8/12/14 | |||
| For Period end: | 6/30/14 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/27/23 Anavex Life Sciences Corp. 10-K 9/30/23 54:5.7M Electro Filings LLC/FA 1/27/23 Anavex Life Sciences Corp. 10-K/A 9/30/22 4:308K Electro Filings LLC/FA 11/28/22 Anavex Life Sciences Corp. 10-K 9/30/22 49:5.1M Electro Filings LLC/FA 11/24/21 Anavex Life Sciences Corp. 10-K 9/30/21 50:13M Electro Filings LLC/FA |